John Martin - 2010 CEO Pay

John C. Martin

John Martin - Gilead Sciences

Total Compensation: $14.2 million

Details: John Martin's compensation was down a little in 2010 from 2009, when his package was worth just under $14.7 million; last year, it was $14.2 million. Martin earned a salary of a little more than $1.3 million last year--up from $1.24 million in 2009. He also received stock and option awards of roughly $10.5 million--down from the previous year, when he snagged more than $11.1 million.

As Dow Jones notes, Gilead is known for its HIV drugs and saw its net income rise 10 percent to $2.9 billion on revenue growth of 13 percent to $7.9 billion.

Gilead Sciences News:
Truvada fails trial to prevent HIV in women
Who's the biggest HIV drug seller of all?

John Martin - 2010 CEO Pay
Read more on

Suggested Articles

New models are needed to assess the value of gene and cell therapies and provide reimbursement, Novartis CEO Vas Narasimhan says.

With stocks tumbling and a price-fixing lawsuit hanging over its head, Mylan’s future is looking spooky. Could a new acquisition help turn the tide?

AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch,…